

Listing of Claims

1. (Canceled)

2. (Currently amended) A substantially purified salivary *P. ariasi* polypeptide, wherein the polypeptide comprises:

a) ~~an~~ the amino acid sequence set forth as SEQ ID NO: 11;

b) ~~a conservative variant of the~~ an amino acid sequence at least 98% identical to the amino acid sequence set forth as SEQ ID NO: 11; or

c) an immunogenic fragment comprising at least fifteen consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 11, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as SEQ ID NO: 11, wherein administration of the polypeptide to a subject produces an immune response to *P. ariasi*.

3. (Currently amended) A substantially purified salivary *P. ariasi* polypeptide, wherein the polypeptide comprises an amino acid sequence at least 98% identical to the amino acid sequence as set forth as SEQ ID NO: 11, or a conservative variant thereof, wherein administration of the polypeptide to a subject produces an immune response to *P. ariasi*.

4. (Currently amended) The *P. ariasi* polypeptide of claim 3, wherein the polypeptide comprises ~~an~~ the amino acid sequence set forth as SEQ ID NO: 11.

5. (Previously presented) An immunogenic fragment of the polypeptide of claim 4, wherein the immunogenic fragment comprises at least fifteen consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 11, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as SEQ ID NO: 11.

6 - 24. (Canceled)

25. (Previously presented) An immunogenic composition comprising an effective amount of the polypeptide of claim 2 and a pharmaceutically acceptable carrier.

26. (Canceled)

27. (Withdrawn and previously presented) A method for inducing an immune response to a *P. ariasi* polypeptide in a subject, comprising:

administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 2, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inducing the immune response.

28. (Withdrawn) The method of claim 27, wherein the immune response comprises a T cell response.

29. (Withdrawn) The method of claim 27, wherein the immune response comprises a B cell response.

30. (Withdrawn) The method of claim 27, wherein the subject comprises a non-human veterinary subject.

31. (Withdrawn) The method of claim 27, wherein the subject is a dog.

32. (Withdrawn) The method of claim 27, wherein the subject is a human.

33. (Withdrawn and previously presented) The method of claim 27, wherein the polypeptide comprises the amino acid sequence set forth as SEQ ID NO:11.

34. (Canceled)

35. (Withdrawn and previously presented) A method for inhibiting a symptom of a *Leishmania* infection or preventing a *Leishmania* infection in a subject, comprising administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of

claim 2, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inhibiting the symptom of the *Leishmania* infection or preventing the *Leishmania* infection.

36. (Withdrawn and previously presented) The method of claim 35, wherein the polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 11.

37 - 79. (Canceled)

80. (Previously presented) The polypeptide of claim 4, wherein the polypeptide consists of an amino acid sequence set forth as SEQ ID NO: 11.

81. (Previously presented) An immunogenic composition comprising an effective amount of the polypeptide of claim 3 and a pharmaceutically acceptable carrier.

82. (Withdrawn and previously presented) A method for inducing an immune response to a *P. ariasi* polypeptide in a subject, comprising
administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 3, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inducing the immune response.

83. (Withdrawn and previously presented) The method of claim 82, wherein the immune response comprises a T cell response.

84. (Withdrawn and previously presented) The method of claim 82, wherein the immune response comprises a B cell response.

85. (Withdrawn and previously presented) The method of claim 82, wherein the subject comprises a non-human veterinary subject.

86. (Withdrawn and previously presented) The method of claim 82, wherein the subject is a dog.

87. (Withdrawn and previously presented) The method of claim 82, wherein the subject is a human.

88. (Withdrawn and previously presented) A method for inhibiting a symptom of a *Leishmania* infection or preventing a *Leishmania* infection in a subject, comprising administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 3, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inhibiting the symptom of the *Leishmania* infection or preventing the *Leishmania* infection.

89. (Withdrawn and currently amended) The method of claim 88, wherein the polypeptide comprises an amino acid sequence at least ~~95~~99% identical to [[a]] the amino acid sequence set forth as SEQ ID NO: 11.

90. (New) The method of claim 89, wherein the polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 11.

91. (New) The method of claim 90, wherein the polypeptide consists of the amino acid sequence set forth as SEQ ID NO: 11.

92. (New) The method of claim 82, wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth as SEQ ID NO: 11.

93. (New) The method of claim 92, wherein the polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 11.

94. (New) The method of claim 93, wherein the polypeptide consists of the amino acid sequence set forth as SEQ ID NO: 11.

95. (New) The substantially purified salivary *P. ariasi* polypeptide of claim 3, wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth as SEQ ID NO: 11.

96. (New) The substantially purified salivary *P. ariasi* polypeptide of claim 2, wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth as SEQ ID NO: 11.

97. (New) The substantially purified salivary *P. ariasi* polypeptide of claim 2, wherein the polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 11.

98. (New) The substantially purified salivary *P. ariasi* polypeptide of claim 2, wherein the immunogenic fragment comprises residues 23-312 of SEQ ID NO: 11.